NICE has recommended a nonsteroidal mineralocorticoid receptor antagonist that lowers worsening heart failure events in adults with preserved or mildly reduced ejection fraction.

Heart failure with preserved ejection fraction (HFpEF) is underdiagnosed in patients with severe secondary tricuspid regurgitation (STR) of undefined etiology (isolated STR), according to a study ...

An international team of researchers at the University of Manchester, Baylor College of Medicine and collaborating institutions has discovered a natural mechanism that protects the heart from heart ...

Thousands of people in England and Wales with a type of chronic heart failure (CHF) could soon be eligible for treatment with ...

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.

DALLAS, September 15, 2025 — The American Heart Association, a relentless force changing the future of health for everyone everywhere, is launching a new initiative to improve in-hospital care for ...

Bayer has welcomed final draft guidance from NICE recommending finerenone for adults in England and Wales with symptomatic chronic heart failure and a left ventricular ejection fraction of 40% or ...

An international team of researchers has discovered a natural mechanism that protects the heart from heart failure with preserved ejection fraction (HFpEF), a serious condition in need of effective ...